A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs Filgrastim (Primary) ; Meloxicam (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 29 Apr 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Nov 2019.
- 31 Aug 2018 Biomarkers information updated
- 12 Mar 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.